Drug maker KemPharm Inc. is on the verge of a company breakthrough.
The Food and Drug Administration in March may approve the Celebration-based company’s attention deficit hyperactivity disorder drug KP415. The treatment stands out from other ADHD treatments on the market because of how quickly it kicks in and how long it lasts, and it may be a financial boost for the pre-revenue company. Read more here.
